Last week, Applied Biosciences announced the completion of a year-long strategic review of its business, wrapping up the process by filling positions among its senior management. But the review process apparently didn’t jump-start revenue growth for the molecular biology tools leader.

“The overall numbers aren’t going up,” said Tony White, CEO of Applera, ABI’s parent company. He said the company modified its revenue projections for FY 2005 to low single-digit growth, from its previous projection of mid-single digit growth.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.